Mr Shingo Matsumoto

  • Affiliate (School of Cardiovascular & Metabolic Health)

Publications

List by: Type | Date

Jump to: 2025 | 2024 | 2023
Number of items: 11.

2025

Akagaki, D. et al. (2025) MAGGIC risk score and drug-related adverse events of sacubitril/valsartan: Insights from the REVIEW-HF registry. International Journal of Cardiology: Heart and Vasculature, 59, 101702. (doi: 10.1016/j.ijcha.2025.101702) (PMID:40476175) (PMCID:PMC12138916)

Chimura, M. et al. (2025) Comprehensive analysis of the effects of sacubitril/valsartan according to sex among patients with heart failure and reduced ejection fraction in PARADIGM‐HF. Journal of the American Heart Association, 14(9), e038249. (doi: 10.1161/JAHA.124.038249) (PMID:40265590)

Gupta, S. D. et al. (2025) Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF. European Journal of Heart Failure, 27(5), pp. 779-787. (doi: 10.1002/ejhf.3515) (PMID:39563094)

Doi, S. et al. (2025) Uptitration of Sacubitril/Valsartan and outcomes in patients with heart failure ― insight from the REVIEW-HF Registry ―. Circulation Journal, 89(1), pp. 93-100. (doi: 10.1253/circj.cj-24-0636) (PMID:39477485)

Matsumoto, S. et al. (2025) Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 27(1), pp. 124-139. (doi: 10.1002/ejhf.3383) (PMID:39215677)

Takigami, Y. et al. (2025) Prognostic impact of sustained reduction of N-Terminal pro-B-type natriuretic peptide after initiating sacubitril/valsartan ― insights from the REVIEW-HF registry. Circulation Reports, 7(6), pp. 433-441. (doi: 10.1253/circrep.cr-25-0029) (PMID:40497122) (PMCID:PMC12148359)

2024

Matsumoto, S. et al. (2024) Relevant adverse events and drug discontinuation of sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry. Journal of Cardiology, 84(2), pp. 133-140. (doi: 10.1016/j.jjcc.2023.11.005) (PMID:38000538)

Matsumoto, S. et al. (2024) Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function. Journal of the American College of Cardiology, 83(24), pp. 2426-2436. (doi: 10.1016/j.jacc.2024.03.426) (PMID:38739064)

Matsumoto, S. et al. (2024) Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF. European Journal of Heart Failure, 26(5), pp. 1125-1138. (doi: 10.1002/ejhf.3223) (PMID:38587090)

2023

Matsumoto, S. et al. (2023) Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 25(12), pp. 2202-2214. (doi: 10.1002/ejhf.3044) (PMID:37771260)

Matsumoto, Shingo, Kondo, Toru, Jhund, Pardeep S. ORCID logoORCID: https://orcid.org/0000-0003-4306-5317, Campbell, Ross T. ORCID logoORCID: https://orcid.org/0000-0002-0050-2129, Swedberg, Karl, van Veldhuisen, Dirk J., Pocock, Stuart J., Pitt, Bertram, Zannad, Faiez and McMurray, John J.V. ORCID logoORCID: https://orcid.org/0000-0002-6317-3975 (2023) Underutilization of mineralocorticoid antagonists in patients with heart failure with reduced ejection fraction. Journal of the American College of Cardiology, 82(11), pp. 1080-1091. (doi: 10.1016/j.jacc.2023.06.021) (PMID:37642608)

This list was generated on Tue Sep 16 00:29:02 2025 BST.
Jump to: Articles
Number of items: 11.

Articles

Akagaki, D. et al. (2025) MAGGIC risk score and drug-related adverse events of sacubitril/valsartan: Insights from the REVIEW-HF registry. International Journal of Cardiology: Heart and Vasculature, 59, 101702. (doi: 10.1016/j.ijcha.2025.101702) (PMID:40476175) (PMCID:PMC12138916)

Chimura, M. et al. (2025) Comprehensive analysis of the effects of sacubitril/valsartan according to sex among patients with heart failure and reduced ejection fraction in PARADIGM‐HF. Journal of the American Heart Association, 14(9), e038249. (doi: 10.1161/JAHA.124.038249) (PMID:40265590)

Gupta, S. D. et al. (2025) Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF. European Journal of Heart Failure, 27(5), pp. 779-787. (doi: 10.1002/ejhf.3515) (PMID:39563094)

Doi, S. et al. (2025) Uptitration of Sacubitril/Valsartan and outcomes in patients with heart failure ― insight from the REVIEW-HF Registry ―. Circulation Journal, 89(1), pp. 93-100. (doi: 10.1253/circj.cj-24-0636) (PMID:39477485)

Matsumoto, S. et al. (2025) Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 27(1), pp. 124-139. (doi: 10.1002/ejhf.3383) (PMID:39215677)

Takigami, Y. et al. (2025) Prognostic impact of sustained reduction of N-Terminal pro-B-type natriuretic peptide after initiating sacubitril/valsartan ― insights from the REVIEW-HF registry. Circulation Reports, 7(6), pp. 433-441. (doi: 10.1253/circrep.cr-25-0029) (PMID:40497122) (PMCID:PMC12148359)

Matsumoto, S. et al. (2024) Relevant adverse events and drug discontinuation of sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry. Journal of Cardiology, 84(2), pp. 133-140. (doi: 10.1016/j.jjcc.2023.11.005) (PMID:38000538)

Matsumoto, S. et al. (2024) Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function. Journal of the American College of Cardiology, 83(24), pp. 2426-2436. (doi: 10.1016/j.jacc.2024.03.426) (PMID:38739064)

Matsumoto, S. et al. (2024) Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF. European Journal of Heart Failure, 26(5), pp. 1125-1138. (doi: 10.1002/ejhf.3223) (PMID:38587090)

Matsumoto, S. et al. (2023) Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 25(12), pp. 2202-2214. (doi: 10.1002/ejhf.3044) (PMID:37771260)

Matsumoto, Shingo, Kondo, Toru, Jhund, Pardeep S. ORCID logoORCID: https://orcid.org/0000-0003-4306-5317, Campbell, Ross T. ORCID logoORCID: https://orcid.org/0000-0002-0050-2129, Swedberg, Karl, van Veldhuisen, Dirk J., Pocock, Stuart J., Pitt, Bertram, Zannad, Faiez and McMurray, John J.V. ORCID logoORCID: https://orcid.org/0000-0002-6317-3975 (2023) Underutilization of mineralocorticoid antagonists in patients with heart failure with reduced ejection fraction. Journal of the American College of Cardiology, 82(11), pp. 1080-1091. (doi: 10.1016/j.jacc.2023.06.021) (PMID:37642608)

This list was generated on Tue Sep 16 00:29:02 2025 BST.